Newly Public Rosetta Genomics Says Q4 R&D Rises 30 Percent; No Revenue Yet

Mar 27, 2007

NEW YORK (GenomeWeb News) — Rosetta Genomics today released its first earnings statement as a new public company, saying it generated no revenues in the fourth quarter, R&D spending increased 30 percentl, and net losses increased 16 percent.

R&D spending for the three months ended Dec. 31, 2006, increased to $1.3 million from $1 million in the year-ago period.

The company said net loss increased to $2.1 million from $1.8 million in the fourth quarter of 2005.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Main menu